

Authorised Prescribers of MDMA and psilocybine

Data current to 31 July 2026

The information below has been extracted from the Therapeutic Goods Administration's internal reporting relating to Authorised Prescriber approvals for MDMA and psilocybine.

Table 1: Authorised Prescribers approved since rescheduling MDMA to Schedule 8 for post-traumatic stress disorder and psilocybine to Schedule 8 for treatment resistant depression

Period: 1 July 2023 to 31 July 2026

Product	Number of unique Authorised Prescribers approved since 1 July 2023
MDMA	63
Psilocybine	60

Table 2: New Authorised Prescribers approved during the most recent completed reporting period

Reporting period: 1 January 2026 to 30 June 2026

Product	Number of new Authorised Prescribers approved
MDMA	17
Psilocybine	22

Methodology and Caveats

The figures were obtained from the TGA's internal reporting for Authorised Prescriber applications relating to MDMA and psilocybine.

The figures represent unique psychiatrists holding an approved Authorised Prescriber approval for the relevant product.

A psychiatrist may hold approvals for both MDMA and psilocybine and may therefore be included in both product categories.

"New Authorised Prescribers" refers to psychiatrists who received their first approval for the relevant product during the period 1 January 2026 to 30 June 2026.

Data is current as at 31/07/2026